2011 Fiscal Year Final Research Report
Basic research on personalized treatment of cancer by HDAC inhibitors
| Project/Area Number |
21590166
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
OZAKI Kei-ichi 長崎大学, 大学院・医歯薬学総合研究科, 准教授 (50252466)
|
|---|
| Research Collaborator |
坂元 利彰 , 大学院生
藤尾 康祐 , 大学院生
梶川 修平 , 大学院生
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | オーダーメード医療 |
|---|
| Research Abstract |
Histone deacetylase(HDAC) inhibitors which are promising anti-tumor agents have high selectivity to the cancer cell in which the ERK-MAP kinase pathway is constitutively activated. The molecular mechanism which results in remarkable HDAC inhibitor sensitivity by blockade of this pathway with MEK inhibitors was clarified. Moreover, in vitro and the animal experiment with xenograft model proved that it is effective also in the cancers which are resistant to some molecular-targeted drugs such as tyrosine kinase inhibitors. It is expected that these results will be useful for the personalized treatment of cancer by HDAC inhibitors.
|
